Greenfern Industries has achieved a revenue of $1 million, representing an increase of 368% over the previous year, and a net loss after tax of $2.03 million, a 1% increase compared to last year.
The company has successfully implemented its strategic plan, which prioritised improving operational efficiency and growth within the Australian prescriber market, and has acquired 1617 new patients while enjoying a return patient rate on average per month of 39%.
Greenfern Industries has also achieved Bcorp certification, secured a binding offtake agreement, maintained its net carbonzero certification, and been part of a trio that was awarded a Bioresource Processing Alliance grant.
Despite the ongoing uncertainty in the global economy, the company remains optimistic about the future and is confident that its efforts will help to achieve its long-term growth objectives.
See more
